Ascentage, spun out of Ascenta Therapeutics and backed by 3SBio, has increased its total funding to more than $240m after closing a $150m series C round.
Ascentage Pharma, a China-based cancer treatment developer spun out of biopharmaceutical company Ascenta Therapeutics, closed a $150m series C round yesterday.
The round was co-led by healthcare-focused investment fund YuanMing Prudence Fund and Oriza Seed Venture Capital, a subsidiary of investment holding firm Suzhou Oriza Holdings.
Teng Yue Partners, ArrowMark Partners, HDY International Investment, CTS Capital and CCB International also took part in the round.
Founded in 2009, Ascentage Pharma is working on therapies for cancer, hepatitis B and age-related…
